Ann: Research partnership with Celularity for solid tumors, page-67

Too many sycophants and worshippers on these boards.

We've even had some try to convince us that the recent Board rip-off of existing shareholders is a "good thing" because it opens the possibility of buying cheaper shares. Next they'll be telling us that "4 legs are good, two-legs better ... baaa, baaa".

Hardly surprising given the way those with an alternate - objective? - view are abused. Stop criticising those with an alternate view of being short-term investors. HER-Vaxx was bought EIGHT years ago. It's already been the long-term for this company, and revenue is no closer than it was in 2013.

The endless "research partnerships" and relentless funding-only-through-CAPITAL-RAISES have caught up with the company. Price-sensitive announcements are now treated with derision as it becomes clearer that there is no revenue for the foreseeable future and that the Board / Management just concentrate on share issue machinations for their wealth. Every research partnership kicks the possibility of a commercial partnership another six months down the road.

After Hopper gets the shares he's not entitled to by forcing through the award of discounted shares to his mates in return for their EGM votes, there will be north of 6 BILLION shares on issue.

So to get to a SP of 50c we need "the dumb market" to value this revenue-less, saleable-product-less company at $3b. Joke.